This report contains market size and forecasts of Ultra Long Acting Insulin in global, including the following market information:
Global Ultra Long Acting Insulin Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Ultra Long Acting Insulin Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Ultra Long Acting Insulin companies in 2021 (%)
The global Ultra Long Acting Insulin market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Insulin Glargine Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Ultra Long Acting Insulin include Sanofi, Eli Lilly, Viatris, Gan&Lee Pharmaceuticals, Tonghua Dongbao Pharmaceutical, United Laboratories International, Novo Nordisk, MNKD and Bristol-Myers Squibb Company, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Ultra Long Acting Insulin manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Ultra Long Acting Insulin Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Ultra Long Acting Insulin Market Segment Percentages, by Type, 2021 (%)
Insulin Glargine
Insulin Detemir
Tresiba
Global Ultra Long Acting Insulin Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Ultra Long Acting Insulin Market Segment Percentages, by Application, 2021 (%)
Type 1 Diabetes
Type 2 Diabetes
Gestational Diabetes
Global Ultra Long Acting Insulin Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Ultra Long Acting Insulin Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Ultra Long Acting Insulin revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Ultra Long Acting Insulin revenues share in global market, 2021 (%)
Key companies Ultra Long Acting Insulin sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Ultra Long Acting Insulin sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Sanofi
Eli Lilly
Viatris
Gan&Lee Pharmaceuticals
Tonghua Dongbao Pharmaceutical
United Laboratories International
Novo Nordisk
MNKD
Bristol-Myers Squibb Company
Emisphere
Biocon